As amounts raised through financings are significantly shy of last year, med-tech deals and M&As appear strong, with digital health dominating the landscape.

Med-tech financings are still down by 55% in comparison with the same time frame last year, but they have gained some ground by narrowing the gap with the pre-pandemic year of 2019.

Medtech Europe, the European trade association for the medical technology industry covering diagnostics, medical devices and digital health, released its latest survey. This study analyses the availability of medical devices in 2022 in light of the Medical Devices Regulation (MDR) being implemented.

Through the second week of August, BioWorld has tracked 439 bio/nonprofit deals worth $6.6 billion, with the bulk of that total coming within the last six weeks through the U.S. government purchasing more vaccines and therapies to fight COVID-19.

BioWorld’s Biopharmaceutical Index is at its highest point this year, up 7.85%, showing one of its sharpest rises within the last week. Out of 22 component stocks, 13 are trading above where they were at the end of 2021, as of Aug. 8. This is an improvement from June, when only nine were in such a position.